太美醫療科技(02576.HK)公佈年度業績 毛利率顯著提升 虧損同比大幅縮窄
格隆匯3月24日丨太美醫療科技(02576.HK)公吿,2024年度,公司聚焦核心競爭力產品以及專注於提升內部經營效率和盈利質量。2024年度,公司的整體業務保持穩定,毛利率顯著提升,虧損淨額以及經調整虧損淨額較去年同期大幅縮窄。2024年度,集團的總收入為人民幣551.2百萬元,毛利率從2023年的31.2%上升至40.8%,提高了9.6個百分點,毛利率顯著提升。公司的年度虧損由2023年的人民幣356.4百萬元收窄至2024年度的人民幣217.4百萬元,同比減虧39.0%。剔除與全球發售有關的上市開支以及以股份為基礎的付款後經調整虧損淨額為57.3百萬元,同比下降81.9%。
截至2024年12月31日,公司已為1400多家醫藥企業及CRO提供服務,覆蓋覆蓋全球25大醫藥企業中的21家及“2024中國醫藥創新企業100強”榜單中的90家。按客户數量計算,公司已成為中國醫藥及醫療器械研發和營銷領域應用最廣泛的數字化解決方案供應商。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.